Neoadjuvant Fluzoparib Combined With Camrelizumab in Germline BRCA-mutated HER2-negative Breast Cancer
Status:
Not yet recruiting
Trial end date:
2026-12-31
Target enrollment:
Participant gender:
Summary
This study is an open-label, single-arm, multicenter clinical study. 94 patients with
germline BRCA-mutated HER2-negative early breast cancer are planned to be enrolled and
treated with fluzoparib combined with camrelizumab to observe and evaluate the efficacy and
safety of neoadjuvant fluzoparib combined with camrelizumab in the treatment of germline
BRCA-mutated HER2-negative early breast cancer。